#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
# Clinical Summary
🏥 While this headline linking vaccines to reduced non-communicable disease rates represents important epidemiological work, the adjacent mention of medicinal cannabis as an oncology treatment warrants clinical caution. Cannabis has shown preliminary promise in managing chemotherapy-related symptoms and potentially slowing growth in some preclinical cancer models, but robust randomized controlled trials demonstrating efficacy and optimal dosing remain limited, and cannabinoid products lack standardized formulations and FDA approval for cancer treatment. Clinicians should be aware that patients increasingly inquire about or self-initiate cannabis use alongside conventional oncology care, which creates risks including drug interactions (particularly with cytochrome P450-metabolized chemotherapy agents), impaired cognitive function affecting treatment adherence, and delayed pursuit of evidence-based therapies. When cannabis use arises in cancer care discussions, providers should inquire non-judgmentally about frequency and type, discuss the evidence gap candidly, monitor for
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
📄 Printable 1-Page Physician Patient Guide
Download or print Dr. Benjamin Caplan’s official clinical reference guide to share with your healthcare team.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
